Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
Cardiovascular Institute of the South · Mount Sinai Medical Center · +12 more institutions
Abstract
inhibitor and aspirin reduces the risk of thrombosis and stroke but increases the risk of bleeding. The effectiveness and safety of anticoagulation with rivaroxaban plus either one or two antiplatelet agents are uncertain.
inhibitor for 12 months (group 1), very-low-dose rivaroxaban (2.5 mg twice daily) plus DAPT for 1, 6, or 12 months (group 2), or standard therapy with a dose-adjusted vitamin K antagonist (once daily) plus DAPT for 1, 6, or 12 months (group 3). The primary safety outcome was clinically significant bleeding (a composite of major bleeding or minor bleeding according to Thrombolysis in Myocardial Infarction [TIMI] criteria or bleeding requiring medical attention).
Citation impact
- FWCI
- 149.17
- Percentile
- 100%
- References
- 13
Authors
17- CMC. Michael GibsonCorresponding
Cardiovascular Institute of the South
- RMRoxana Mehran
Cardiovascular Institute of the South, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai
- CBChristoph Bode
Cardiovascular Institute of the South, University of Freiburg
- JLJonathan L. Halperin
Cardiovascular Institute of the South, Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center
- FWFreek W.A. Verheugt
Cardiovascular Institute of the South, Amsterdam University of Applied Sciences
Topics & keywords
- Conventional PCI
- Atrial fibrillation
- Cardiology
- Medicine
- Internal medicine
- Myocardial infarction
- Good health and well-being